Abstract

Serious intraocular toxicity cases have been reported worldwide after the use of different perfluorocarbon liquids. The current study reports for the first-time the clinical pictures of cases of acute intraocular toxicity caused by MEROCTANE, a perfluoro-octane commercialized by a Turkish company and distributed in many countries. A series of 18 cases from Chile and Spain was retrospectively analysed. To evaluate the impurity profile, a suspicious MEROCTANE sample (lot OCT.01.2013) was analysed by gas chromatography mass spectrometry and compared with a non-suspicious sample of the same commercial perfluoro-octane (lot OCT 722011). Cytotoxicity was tested following a direct-contact method, taking into consideration the high volatility and hydrophobicity of perfluoro-octane and following the ISO 10993 guideline. Cytotoxicity test showed clear cytotoxic effects of the analysed batch (less than 9% of cell viability). Moreover, chemical analysis demonstrated the presence of many contaminants, some highly toxic (acids and alcohols). Perfluorocarbon liquids are useful tools for intraocular surgery but companies and Agencies of Medical Devices must implement measures that guarantee the safety of these products based on both chemical and cytotoxicity analysis for every batch. Medical staff should be encouraged to report any suspected case to their respective National Agencies.

Details

Title
Intraocular toxicity caused by MEROCTANE perfluorocarbon liquid
Author
Coco-Martin, Rosa M 1 ; Andrés-Iglesias, Cristina 2 ; Srivastava, Girish K 2 ; Lagos-Rodriguez, Javier 3 ; Ruiz-Tevah, Miguel 4 ; Díaz-Cárdenas, Mario R 5 ; Fernandez-Bueno, Ivan 2 ; García-Serna, Juan 6 ; García-Gutierrez, María T 2 ; García-Layana, Alfredo 7 ; Carlos, Pastor J 8 

 University of Valladolid, Instituto Universitario de Oftalmobiología Aplicada (IOBA), Eye Institute, Valladolid, Spain (GRID:grid.5239.d) (ISNI:0000 0001 2286 5329); Oftared, Carlos III National Institute of Health, Madrid, Spain (GRID:grid.417198.2) (ISNI:0000 0000 8497 6529) 
 University of Valladolid, Instituto Universitario de Oftalmobiología Aplicada (IOBA), Eye Institute, Valladolid, Spain (GRID:grid.5239.d) (ISNI:0000 0001 2286 5329) 
 Hospital Regional Liberador Bernardo O’Higgins and Clínica Vision, Rancagua, Chile (GRID:grid.5239.d) 
 Hospital San Borja Arriarán and Instituto de La Visión, Santiago, Chile (GRID:grid.413359.9) (ISNI:0000 0004 0628 8949) 
 Hospital Clínico and University of Magallanes, Punta Arenas, Chile (GRID:grid.442242.6) (ISNI:0000 0001 2287 1761) 
 University of Valladolid, High Pressure Process Group, Departamento de Ingeniería Química y Tecnología del Medio Ambiente, Instituto de Bioeconomía, Valladolid, Spain (GRID:grid.5239.d) (ISNI:0000 0001 2286 5329) 
 Oftared, Carlos III National Institute of Health, Madrid, Spain (GRID:grid.417198.2) (ISNI:0000 0000 8497 6529); Clínica Universitaria de Navarra and University of Navarra, Department of Ophthalmology, Pamplona, Spain (GRID:grid.411730.0) (ISNI:0000 0001 2191 685X) 
 University of Valladolid, Instituto Universitario de Oftalmobiología Aplicada (IOBA), Eye Institute, Valladolid, Spain (GRID:grid.5239.d) (ISNI:0000 0001 2286 5329); Oftared, Carlos III National Institute of Health, Madrid, Spain (GRID:grid.417198.2) (ISNI:0000 0000 8497 6529); Hospital Clínico Universitario, Department of Ophthalmology, Valladolid, Spain (GRID:grid.411057.6) (ISNI:0000 0000 9274 367X) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2477090850
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.